`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`QUALICAPS CO., LTD.,
`Patent Owner.
`
`
`
`Case No. IPR2017-00203
`Patent No. 6,649,180
`
`PATENT OWNER’S OPPOSITION TO PETITIONER MYLAN
`PHARMACEUTICALS INC.’S MOTION FOR ADDITIONAL
`DISCOVERY UNDER 37 C.F.R. § 42.51(b)(2)
`
`
`
`
`
`
`
`
`
`
`
`
`DC: 6503304-6
`
`
`
`
`
`IPR2017-00203
`
`Petitioner requested authorization “to file a motion for additional discovery in
`
`the form of Mr. Tanjoh’s deposition . . .” based on Mr. Tanjoh’s prosecution history
`
`declaration. See Ex. 2061 (emphasis added). Petitioner’s motion, however, seeks
`
`additional discovery not only in the form of the deposition of Mr. Masaru Tanjoh,
`
`but also “production of all documents . . . supporting or refuting Patent Owner’s
`
`assertion that the invention of the U.S. Patent No. 6,649,180 (“the ’180 [P]atent”)
`
`yielded unexpected results.” Paper 31 at 1. Neither Petitioner’s request for additional
`
`discovery, nor the Board’s authorization, addressed the production of documents.
`
`See Ex. 2061. Petitioner tries to justify this expanded request by stating that the
`
`documents in question go to Patent Owner’s showing of unexpected results. This
`
`rationale is misplaced. Petitioner has already deposed Patent Owner’s expert, Dr.
`
`McConville, the witness in this proceeding who actually opined on “unexpected
`
`results.” Moreover, Patent Owner has already consented to filing the March 2017
`
`transcript from Mr. Tanjoh’s litigation deposition in the present proceeding (Ex.
`
`2062 at 3-5), which Petitioner concedes is a sufficient alternative to a second
`
`deposition (Paper 31 at 1 & 7). Because Petitioner’s remaining request for litigation-
`
`produced documents was unauthorized, there is effectively nothing left to decide.
`
`I.
`
`BACKGROUND
`The declaration that formed the basis of Petitioner’s request for additional
`
`discovery is not one prepared for purposes of this proceeding. Rather, it is a short
`
`1
`
`
`
`IPR2017-00203
`
`declaration from an inventor, Mr. Tanjoh, submitted during the original prosecution
`
`of the ’180 patent. (“Tanjoh Declaration”; Ex. 1010 at 105–108). The declaration
`
`reports data and test results from Mr. Tanjoh’s experiments, the accuracy of which
`
`Petitioner’s own expert does not contest. Ex. 2029 at 114:7–23. Mr. Tanjoh does not
`
`opine on whether the reported data and test results would have been surprising or
`
`unexpected to a POSA, and Petitioner cites to no testimony of Mr. Tanjoh to that
`
`effect. Rather, it is Dr. McConville who opines on the unexpected and surprising
`
`nature of Mr. Tanjoh’s test results. Compare Paper 31 at 2 (quoting Mr. Tanjoh’s
`
`test results from Ex. 1010 at 107), id. at 4 (no citation to where “the inventor’s self-
`
`serving testimony that the claim possesses surprising or unexpected import” appears,
`
`much less a cite to the Tanjoh Declaration), and id. at 5 (no citation to where Mr.
`
`Tanjoh “assert[ed] surprising or unexpected results”), with id. at 2 (“He [Dr.
`
`McConville] concludes that ‘the POSA would have found this result surprising an[d]
`
`unexpected’” (emphasis added), citing to McConville Declaration, Ex. 2028 at ¶¶
`
`99–100). Petitioner deposed Dr. McConville on August 17, 2017.
`
`As Petitioner acknowledges, in the related district court litigation (Civil
`
`Action Nos. 2:15-cv-1471; 2:15-cv-1740 (E.D. Tex.)), Mr. Tanjoh was designated
`
`to testify regarding, among other things, unexpected results as an objective indicia
`
`of nonobviousness of the ‘180 Patent. Paper 31 at 4–5; see also Ex. 1024 at 6 (Topic
`
`17 includes unexpected results); Ex. 1025 at 2 (confirming Topic 17 for testimony
`
`2
`
`
`
`IPR2017-00203
`
`by Mr. Tanjoh). Petitioner’s back-up counsel in the present proceeding, Mr. Olinger,
`
`conducted Mr. Tanjoh’s litigation deposition in March of this year, during which a
`
`number of deposition exhibit documents were identified as “RESTRICTED—
`
`ATTORNEYS’ EYES ONLY” (“the AEO Exhibits”).
`
`II.
`
`ARGUMENT
`Each of the five Garmin factors, which frame the analysis for determining
`
`whether additional discovery is in the interests of justice and should thus be allowed,
`
`fails to support either the cross-examination of Mr. Tanjoh, or the requested
`
`production of documents. See Garmin Int’l Inc. v. Cuozzo Speed Techs. LLC, Case
`
`IPR2012-00001, Paper 26 (PTAB March 5, 2013).
`
`A. Garmin factor #1: Petitioner has failed to show that there is more
`than a possibility or mere allegation that something useful will be
`uncovered by deposing Mr. Tanjoh for a second time.
`Contrary to Petitioner’s assertion, the Tanjoh Declaration does not opine on
`
`whether the data and results reported therein would be surprising or unexpected to a
`
`POSA. See Ex. 1010 at 105–108. Petitioner’s motion cites to no testimony of Mr.
`
`Tanjoh to that effect. See Paper 31 at 2, 4, & 5. Therefore, Petitioner has not shown
`
`that something “useful” will be obtained from the cross-examination. In addition,
`
`Petitioner specifically required Mr. Tanjoh to be prepared to discuss any knowledge
`
`he had bearing on “unexpected results” during the March 2017 litigation deposition
`
`(Ex. 1024 at 6), by which time Petitioner was in possession of the Patent Owner
`
`3
`
`
`
`IPR2017-00203
`
`Preliminary Response (“POPR”; Paper 9, February 17, 2017) that laid out the
`
`unexpected results arguments from the present proceeding (Paper 9 at 1, 4–11, 13–
`
`14, 17).
`
`Patent Owner has already consented to filing in the present proceeding Mr.
`
`Tanjoh’s complete sworn testimony from the March 2017 litigation deposition. Ex.
`
`2062 at 3-5. Thus, any testimony from Mr. Tanjoh regarding unexpected results, and
`
`the AEO Exhibits, would be included in the deposition transcript, and the record of
`
`Mr. Tanjoh’s testimony would be complete. Petitioner’s “extremely unburdensome
`
`request” (Paper 31 at 1) for consent to file the AEO Exhibits from Mr. Tanjoh’s
`
`March deposition, along with the complete sworn testimony and the non-AEO
`
`deposition exhibits, is nothing more than a back-door attempt to obtain documents
`
`through additional discovery that were not requested, much less authorized by the
`
`Board. See Ex. 2061.
`
`Significantly, Petitioner has not asserted or alleged that any of the AEO
`
`Exhibits is directed to the data and experiments contained in the Tanjoh Declaration,
`
`much less directed to why such results are surprising or unexpected, as opposed to
`
`any of the other numerous topics on which Mr. Tanjoh was deposed. See Exs. 1024,
`
`1025. Petitioner’s rationale that a protective order would solve confidentiality
`
`concerns about the AEO Exhibits misses the point. Petitioner has not, and cannot,
`
`establish that they are independently entitled to production of the AEO Exhibits
`
`4
`
`
`
`IPR2017-00203
`
`
`under the rules of additional discovery in IPR proceedings.
`
`B. Garmin factor #2: Petitioner is seeking Patent Owner’s litigation
`positions and the underlying basis for those positions.
`The fact that Petitioner finds the complete sworn testimony of Mr. Tanjoh
`
`inadequate to meet their needs is telling—Petitioner seeks a “do-over” of the first
`
`Tanjoh deposition to gain more favorable testimony for use in the related litigation.1
`
`Thus, Petitioner’s request violates the Board’s “established rules for the presentation
`
`of arguments and evidence” and is thus not in the interest of justice. Garmin, Case
`
`IPR2012-00001, Paper 26 at 6.
`
`C. Garmin factor #3: Petitioner has the ability to generate equivalent,
`and more relevant, information by other means.
`Petitioner seeks additional discovery regarding the unexpected and surprising
`
`results of the claimed invention in the ’180 patent. Paper 31 at 1, 7. However, as the
`
`motion acknowledges, it is Dr. McConville who opines that the results reported in
`
`the Tanjoh Declaration were surprising and unexpected to a POSA. Paper 31 at 2,
`
`citing Ex. 2028 at ¶¶ 99–100. Patent Owner relies not on the AEO Exhibits, but on
`
`
`1 The Protective Order in the litigation precludes use of the litigation deposition in
`
`the IPR absent consent, which Patent Owner provided, agreeing to work with
`
`Petitioner on a Protective Order for the IPR with respect to the filing of the March
`
`2017 deposition transcript. Ex. 2062 at 4-5.
`
`5
`
`
`
`IPR2017-00203
`
`the declaration of Dr. McConville (Ex. 2028) and the documents cited therein, to
`
`support its position regarding unexpected results. Petitioner deposed Dr. McConville
`
`on August 17, 2017, completing the deposition in less than the allotted seven hours.
`
`Thus, Petitioner has had a full opportunity to test with cross-examination Patent
`
`Owner’s evidence of unexpected results. In addition, Petitioner had a full
`
`opportunity to question Mr. Tanjoh on the issue of “unexpected results” in the March
`
`2017 deposition (Exs. 1024, 1025), and Patent Owner has consented to filing of his
`
`complete sworn testimony from that deposition in the present proceeding.
`
`D. Garmin factor #4: Petitioner’s additional request for all
`documents relating to unexpected results is not easily
`understandable.
`Not only is the request for “all documents” relating to unexpected results
`
`unauthorized by the Board (Ex. 2061), it is unduly broad (requesting “all
`
`documents”), vague (requesting any documents that “support or refute [Patent
`
`Owner’s] assertion of unexpected results”), and, by Petitioner’s own admission, a
`
`“litigation” document request (Paper 31 at 7 referencing “similar requests in the
`
`underlying district court litigation”) inappropriate for an IPR proceeding.
`
`E. Garmin factor #5: Petitioner’s request is overly burdensome and
`not in the interest of justice.
`It cannot be in the interest of justice, and is certainly unduly burdensome, to
`
`require a second deposition of Mr. Tanjoh with respect to a declaration from the
`
`original prosecution, and any “unexpected results” as an objective indicia of
`
`6
`
`
`
`IPR2017-00203
`
`nonobviousness, of the ‘180 Patent, when Petitioner had the opportunity to question
`
`Mr. Tanjoh on these very topics, and Patent Owner has consented to the filing of the
`
`complete testimony from that two-day deposition in the present proceeding. Mr.
`
`Tanjoh is approximately 70 years old and resides in Japan, and requires an interpreter
`
`in order to be deposed. Petitioner’s request to produce all documents that “support
`
`or refute the assertion of unexpected results,” (Paper 31 at 7) is unduly burdensome
`
`because it is not “sensible and responsibly tailored according to a genuine need.”
`
`Garmin, Case IPR2012-00001, Paper 26 at 7.
`
`Given that Patent Owner has consented to the filing of the complete transcript
`
`of Mr. Tanjoh’s testimony from the March 2017 deposition, Petitioner has not
`
`established a genuine need for a second deposition, particularly since Petitioner has
`
`already deposed Dr. McConville, the witness in this proceeding who actually opined
`
`on “unexpected results.” In addition, Petitioner has not established a genuine need
`
`for the AEO Exhibits given that (i) the record of Mr. Tanjoh’s testimony would be
`
`complete, (ii) Patent Owner does not rely on the AEO Exhibits as evidence of
`
`unexpected results, (iii) Petitioner has not asserted that any of the AEO Exhibits is
`
`directed to the Tanjoh Declaration data and experiments, and (iv) Petitioner has
`
`tested with the cross-examination of Dr. McConville the evidence on which Patent
`
`Owner relies for “unexpected results.” Petitioner’s request for the cross-examination
`
`of Mr. Tanjoh and for production of the AEO Exhibits should be denied.
`
`7
`
`
`
`Date: August 18, 201.7
`
`Respectfully submitted,
`
`lPR2017—00203
`
`By
`
`
`
`
`
`
`
`6)
`No.86“,
`Jessica L.
`'glrezéfu (Reg
`Andrea G. l eister (Reg. No. 36,253)
`Scott E. Kamholz (Reg. No. 48,543)
`Michael N. Kennedy (pro hac vice)
`Megan P. Keane (pro hac vice)
`COVINGTON & BURLENG LLP
`
`”
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`
`MaryAnne Armstrong (Reg. No. 40,069)
`Lynde F. Herzbach (Reg. No. 74,886)
`BIRCH, STEWART, KOLASCH & BIRCH, LLP
`8110 Gatehouse Road, Suite- 100 East
`
`Falls Church, VA 22042
`
`(703) 205-8000
`
`Attorneys for Patent Owner
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CPR. § 42.6, I hereby certify that on this 18th day of August
`
`2017,
`
`the
`
`foregoing Patent Owner’s Opposition To Petitioner Mylan
`
`Pharmaceuticals Inc.’s Motion For Additional Discovery Under 37 C.F.R.
`
`§42.51(b)(2) was served via electronic mail, by agreement of the parties, on the
`
`following counsel ofrecord for Petitioner.
`
`Mitchell G. Stockwell
`
`David C. Holloway
`Jonathan D. Olinger
`Miranda C. Rogers
`Mylan—WC—IPR@kilpatricktownsendeom
`Kilpatrick Townsend & Stockton LLP
`1 100 Peachtree Street, Suite 2800
`
`Atlanta, GA 30309
`
`Dated: August ES, 2017
`
`Rebistration No.: 50,286
`
`